Coastal Bridge Advisors LLC Acquires Shares of 14,500 Halozyme Therapeutics, Inc. $HALO

Coastal Bridge Advisors LLC bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, HoldingsChannel.com reports. The fund bought 14,500 shares of the biopharmaceutical company’s stock, valued at approximately $1,135,000.

Other large investors also recently modified their holdings of the company. Empowered Funds LLC acquired a new stake in shares of Halozyme Therapeutics in the first quarter valued at approximately $755,000. Acadian Asset Management LLC acquired a new position in Halozyme Therapeutics during the 1st quarter worth $195,000. Hsbc Holdings PLC boosted its position in Halozyme Therapeutics by 117.1% in the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after buying an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 174 shares during the period. Finally, Baird Financial Group Inc. increased its stake in shares of Halozyme Therapeutics by 6.2% in the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after buying an additional 650 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $79,987,320.40. This trade represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the transaction, the director owned 40,418 shares of the company’s stock, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 64,103 shares of company stock valued at $5,226,496. 2.50% of the stock is currently owned by company insiders.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $106.92 on Friday. The firm has a fifty day moving average of $86.27 and a two-hundred day moving average of $74.57. The stock has a market capitalization of $12.14 billion, a price-to-earnings ratio of 31.92, a PEG ratio of 0.43 and a beta of 0.85. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $109.66. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the prior year, the business posted $1.54 EPS. The firm’s quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities research analysts predict that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on HALO shares. HC Wainwright boosted their target price on Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Morgan Stanley lowered their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Finally, UBS Group restated a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $91.20.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.